07 Jan 2001

MAXALT® 5 (MAXALT® 5 mg/-10 mg Tabletten) - Deutschland

Updated: 07 Jan 2001

MAXALT® 5 mg | -10 mg; lingua 5 mg | -10 mg

Akute Behandl. der Kopfschmerzphase von Migräneanfällen mit od. ohne Aura.

MAXALT® 5 Description, Presentation and Dosage

MAXALT® 5 Description

MAXALT® 5 Drug Class Description

Einzelstoffe

MAXALT® 5 Drug Description

1 Tbl. enth.: Rizatriptanbenzoat 7,265 mg/14,53 mg (entspr. 5 mg/10 mg Rizatriptan).

MAXALT® 5 Generic Name

MAXALT® 5 mg/-10 mg Tabletten

MAXALT® 5 Presentation

MAXALT® 5 Presentation

MAXALT® 5 mg/-10 mg; lingua 5 mg/-10 mg

MAXALT® 5 Manufacturer

MSD

Related Learning Zones

IL-17A in Psoriasis Knowledge Centre

IL-17A in Psoriasis Knowledge Centre

IL-17A in Psoriasis is intended for healthcare professionals involved in the treatment and management of patients with psoriasis. This resource has been developed primarily to discuss the role of the IL-17 pathway in the pathogenesis of psoriasis and the therapeutic potential of treatments directed towards IL-17A. Users can expect to find sections containing expert videos, clinical slide decks, congress highlights, key publications and links to useful resources.

This resource has been developed in collaboration with Novartis Pharma AG.

Type 2 Diabetes Knowledge Centre and CME

Type 2 Diabetes Knowledge Centre and CME

The Type 2 Diabetes Learning Zone comprises the Type 2 Diabetes Mellitus Knowledge Centre containing current epidemiology statistics, current diagnosis criteria from WHO and ADA, treatment options and latest guidelines; a Therapy Focus area compiling material on emerging insulin/incretin treatment combinations; and two free CME activities, which are the EACCME-accredited ‘Role of Newer Therapies for Type 2 Diabetes in Combination with Insulin’ (worth 1 CME credit) and ‘Best Practice in Type 2 Diabetes: Update on Incretin Therapies in Combination with Insulin’. 

MAXALT® 5 Dosage

MAXALT® 5 Adult Dosage

Lactose 1H2O, mikrokristalline Cellulose, Maisquellstärke, Eisen(III)-oxid, rot (E 172), Magnesiumstearat.

MAXALT® 5 Child Dosage


MAXALT® lingua 5 mg/-10 mg Schmelztabletten
Zus.: 1 Schmelztbl. enth.: Rizatriptanbenzoat 7,265 mg/14,53 mg (entspr. 5 mg/10 mg Rizatriptan).
Weit. Bestandteile: Gelatine, D-Mannitol, Glycin, Aspartam, Pfefferminzaroma.

MAXALT® 5 Precautions, Reactions and Contraindications

MAXALT® 5 Special Precautions

MAXALT® 5 Special Precautions

Schwere Leberfunktionseinschränkung, schwere Niereninsuffizienz, Pat. mit einem zerebrovaskulären Ereignis/TIA in der Krankheitsgeschichte, mäßige od. schwere Hypertonie od. unbehandelte leichte Hypertonie, ischämische Herzkrankheit (Angina pectoris, Herzinfarkt in der Vorgeschichte, dokumentierte stumme Ischämie), Anzeichen od. Symptome einer ischämischen Herzerkrankung, Prinzmetal Angina, periphere Gefäßerkrankung, gleichz. Verabreichung von Ergotamin, Ergotaminderivaten (einschließl. Methysergid) od. anderen 5-HT1B/1D-Rezeptoragonisten, gleichz. Verabreichung von MAO-Hemmern od. Einsatz innerhalb von 2 Wo. nach Absetzen einer MAO-Hemmer-Therapie.

Related Drugs - Neurological Disorders

Back to top